Improved Nerve Agent Treatment System

INATS

Description

The Improved Nerve Agent Treatment System (INATS) is an enhanced treatment regimen designed to provide protection against a broad spectrum of nerve agents. The components of INATS include (1) replacing the currently fielded oxime (2-pralidoxime chloride, 2-PAM) with a new oxime and (2) obtaining U.S. Food and Drug Administration (FDA) approval for use of pyridostigmine bromide (PB), the component of Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP) for use against additional nerve agents. The current pretreatment indication for SNAPP is limited to soman. The new oxime is intended to replace 2-PAM in the currently fielded Antidote Treatment-Nerve Agent Autoinjector (ATNAA) or similar device. INATS will not eliminate the need for other protective and therapeutic systems. INATS is intended for self or buddy administration.

Mission

Provide protection against nerve agent-induced symptoms of toxicity, such as: breathing difficulties, hypersecretions, muscle tremors, and death.

Capability: Treat the effects of nerve agent intoxication.

Improvements ofver the ATNAA and SNAPP: Improved oxime effectiveness against additional agents, and expanded indication for pretreatment against broad spectrum of nerve agents.

Capabilities

Users

US Navy, US Marine Corps, US Army, US Air Force

Status

Technology Development - Anticipated Fielding: FY 2019 Q2

This Fact Sheet was cleared for public release on 1/22/2013.
Point of Contact: Chemical, Biological, Radiological, & Nuclear Information Resource Center (CBRN IRC), CBRN.IRC@us.army.mil,
Toll Free: 1-800-831-4408, Commercial: (309) 782-7349, DSN: 793-7349, Fax: (309) 782-1919